A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis.

Trial Profile

A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Momelotinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 06 Dec 2016 Results of 6 years follow up data (n=100) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Results of retrospective analysis (n=100) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Dec 2013 Efficacy and tolerability outcomes according to average daily dose presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top